Work

Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps5069

Authors: Mary-Ellen Taplin, Emmanuel S. Antonarakis, Daniel T. Dransfield, Karen J. Ferrante, Johann Sebastian De Bono

Institutions: Harvard University, Dana-Farber Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Tokai Pharmaceuticals (United States), Royal Marsden NHS Foundation Trust, Institute of Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2604894662

Cites:

Cited by: 7

Related to: 10